Singapore Medical Group in the pink of health
The Catalist-listed company today has a market capitalisation of over S$200 million, and has been profitable since FY2016.
Add BT as a preferred source
THESE days Singapore Medical Group (SMG) barely resembles the once ailing entity that it was.
In 2013, the Catalist-listed group faced significant headwinds and losses due to the changing medical landscape in Singapore: declining medical tourism, changing economics of healthcare and growing trend of consolidation of medical practices.
The same year, SMG chief executive officer Dr Beng Teck Liang and his partners, including SMG chairman Tony Tan Choon Keat, a founder of Singapore's Parkway Holdings, acquired a controlling shareholding of SMG and set out a three-year plan to rebuild the business.
TRENDING NOW
Simba ordered to pay S$700,000 in damages to indoor skydiving operator Altitude Xperience for trespass
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
What’s wrong with Orchard Road? Experts weigh in on the street’s cachet and its future
Back to Earth for SpaceX? Why the US$2 trillion titan shed US$600 billion in 3 days
